Pig Kidneys Transplanted into Humans: Where Xenotransplantation Stands in 2026

Transplanting a pig organ into a person is no longer only an experiment in a deceased body. Teams have implanted genetically modified kidneys into living recipients under controlled regulatory pathways. Some organs produced urine and allowed discharge from hospital. That demonstrates biological function, not yet a durable answer to organ shortage.

Why pigs?

Their organs are a compatible size, husbandry is established and reproduction is rapid. An animal donor could provide a planned, tested organ at the required time instead of waiting for a compatible human donor.

The human immune system, however, recognises pig molecules as foreign and may destroy the organ rapidly. Genetic modifications remove certain antigens, add human proteins that regulate immunity and coagulation, and may limit organ growth.

What the first cases showed

Massachusetts General Hospital reported a second transplant of a genetically edited pig kidney into a living recipient after its first case in 2024. NYU Langone also described a recipient returning home; the institution later said the kidney was removed after 130 days when it no longer functioned sufficiently.

These cases provide essential information about surgery, immunosuppression and follow-up. They remain individual cases, some under compassionate pathways. Duration, complications and removal reasons matter as much as initial function.

The three major risks

The first is rejection, immediate or progressive. Even with multiple edits, additional immune targets may emerge, while anti-rejection drugs expose patients to infection and toxicity.

The second is coagulation and physiology. A pig kidney must interact for months with human hormones, blood vessels and metabolism. Early measured function does not guarantee a durable balance.

The third is infection. Donor animals are raised in controlled facilities and screened for pathogens. Retroviruses embedded in the pig genome receive special monitoring. The risk concerns the recipient and, in theory, public health, which justifies long follow-up.

Why formal trials are essential

A trial defines entry criteria, the pig product, medicines, examinations, adverse events and stopping rules in advance. It allows several patients to be compared under the same protocol. Without that, very different cases cannot produce a reliable success rate.

FDA guidance covers source animals, manufacturing, microbiological controls and surveillance. Editing the pig is one part of the product; breeding, transport and traceability are also part of it.

Will xenotransplantation replace human donation?

Not soon. A well-matched human kidney has decades of evidence and remains the reference. Xenotransplantation may initially serve people without a reasonable option, far from a donor organ or difficult to maintain on dialysis. Its role depends on functional duration, risk and cost.

It also does not replace kidney-disease prevention, donation, better preservation or artificial kidneys. Several approaches may reduce the same shortage.

The verdict

Evidence in 2026 is stronger than it was several years ago: an edited pig kidney can support a living human body for a meaningful period. What remains unknown is reproducible duration, the best set of edits and the balance between immunosuppression and rejection.

The next meaningful milestone is a series of trials with a common protocol, complete results and extended follow-up—not only a new individual record. For another technology that changes living cells, read our CRISPR therapy dossier.